US · Healthcare · Biotechnology
EPS came in at -0.55 against a street estimate of -0.49 — a miss of 12.2%.
Analysts rate Oruka Therapeutics, Inc. a strong buy (8 buy, 0 hold, 0 sell out of 8) with an average price target of $155.00.
| Fund | Stake |
|---|---|
| FMR Inc | 11.22% |
| VR Adviser, LLC | 6.27% |
| Fairmount Funds Management LLC | 5.60% |
| BlackRock Inc | 5.33% |
| Capital World Investors | 5.14% |
| Viking Global Investors LP | 4.03% |
| Paradigm Biocapital Advisors LP | 3.24% |
| RTW INVESTMENTS, LLC | 3.11% |
| Document | Date |
|---|---|
| Board / officer change · Q3 2026 ORUKA THERAPEUTICS, INC. – FORM 8-K SUMMARY BUSINESS & SEGMENT HIGHLIGHTS • New Chief Commercial Officer Appointment: Todd Edwards commenced employm | 2026-08-24 |
| Quarterly report · Q2 2026 ORUKA THERAPEUTICS, INC. - Q2 2026 10-Q SUMMARY HEADLINE NUMBERS • Cash position: $268.5 million in cash and cash equivalents as of June 30, 2026, u | 2026-08-10 |
| Results announced · Q3 2026 ORUKA THERAPEUTICS Q2 2026 FINANCIAL RESULTS & CORPORATE UPDATE HEADLINE NUMBERS • Cash Position: $1.1 billion in cash, cash equivalents, and market | 2026-08-10 |
| Shareholder vote results · Q2 2026 ORUKA THERAPEUTICS, INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • Annual Meeting of Stockholders held June 2, 2026 • Company trades on Nasdaq Global Ma | 2026-06-04 |
| Company announcement · Q2 2026 ORUKA THERAPEUTICS, INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • Company: Oruka Therapeutics, Inc. (Nasdaq: ORKA) • Filing Date: June 1, 2026 (Event D | 2026-06-01 |
| Quarterly report · Q1 2026 ORUKA THERAPEUTICS, INC. – Q1 2026 10-Q SUMMARY HEADLINE NUMBERS • Cash & Marketable Securities: $496.0 million total as of March 31, 2026 ($49.5M c | 2026-05-13 |
| Proxy statement · Q2 2026 ORUKA THERAPEUTICS, INC. – 2026 PROXY STATEMENT SUMMARY WHAT SHAREHOLDERS ARE VOTING ON • Proposal 1: Election of Two Class II Directors – Elect two | 2026-04-17 |
| Annual report FY2025 ORUKA THERAPEUTICS, INC. – FORM 10-K SUMMARY (Fiscal Year 2025) HEADLINE NUMBERS • Market capitalization (as of June 30, 2025): approximately $371.5 | 2026-03-12 |
Readable in the app.
| Action | Detail | Date |
|---|---|---|
| Split | 1 : 12 effective Sep 3, 2024 | 2024-09-03 |
| Announcement | Date |
|---|---|
| Phase 3 program expected to begin in 1H 2027; multiple clinical catalysts ahead Oruka Therapeutics, a clinical-stage biotech company, reported progress on its pipeline of treatments for skin diseases like psoriasis and hidradenitis suppurativa. Key highlights: ORKA-001 | 2026-08-10 |
| First amendment to IL-23 license agreement between parties Paragon Therapeutics and Oruka Therapeutics amended their IL-23 license agreement dated December 17, 2024. The key changes expand Paragon's rights while giving Oruka more development flexibi | 2026-06-01 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Oruka Therapeutics, Inc. — free to start.
Google PlayApp StoreData updated 2026-09-18.